NewLeaf Symbiotics
PrivateLast Round
Series D
Dec 19, 2023
Total Funding Raised
$141M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NewLeaf Symbiotics is an agricultural biotechnology company that develops and commercializes sustainable agricultural products based on beneficial bacteria to help farmers fight plant disease and increase crop yields.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Sustainable Materials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NewLeaf Symbiotics Comparables
Compare NewLeaf Symbiotics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioConsortia, Inc. | 81% | |
| Locus Fermentation Solutions | 78% | |
| Sound | 78% |
NewLeaf Symbiotics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 19, 2023 | ||||
| Series D | Dec 1, 2020 | ||||
| Series D | Feb 24, 2020 | ||||
| Series C | Sep 7, 2017 | ||||
| Series B | Sep 17, 2014 | ||||
Series A | Jan 10, 2013 |
Key People
Founding team and executive leadership
NewLeaf Symbiotics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RockPort Capital Partners | Series D, Series A, Series C, Series B |
| Open Prairie | Series A, Series C, Series B |
| Open Prairie Ventures | Series C, Series B, Series A |
| Re:food | Series D |
| The Yard Ventures | Series C |
| Lewis & Clark Partners | Series C |
| Lewis & Clark Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 93% MoM.
- Jul 1, 2026
Launching a new biostimulant for vegetable transplants on July 1, 2026.
NewLeaf Symbiotics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NewLeaf Symbiotics's valuation, stock price, and market status.
Is NewLeaf Symbiotics a public or private company?
NewLeaf Symbiotics is a private company.
What is the current stock price of NewLeaf Symbiotics?
NewLeaf Symbiotics is a private company with no public stock price. No recent secondary market data is available.
How much is NewLeaf Symbiotics worth (valuation)?
Valuation information for NewLeaf Symbiotics is not publicly available.
Can I buy NewLeaf Symbiotics stock?
NewLeaf Symbiotics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NewLeaf Symbiotics's last funding round?
NewLeaf Symbiotics's most recent funding round was Series D on December 19, 2023.
Who are the main investors in NewLeaf Symbiotics?
Key investors in NewLeaf Symbiotics include Open Prairie Ventures, S2G Investments, Leaps by Bayer, Otter Capital.
Will NewLeaf Symbiotics IPO soon?
No public IPO plans have been announced for NewLeaf Symbiotics.
How can I track NewLeaf Symbiotics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NewLeaf Symbiotics's secondary market activity and sign up for updates.